REVIEW Vitamin D, Obesity and Risk of Diabetes · 2017. 1. 4. · della vitamina D, e raramente...
Transcript of REVIEW Vitamin D, Obesity and Risk of Diabetes · 2017. 1. 4. · della vitamina D, e raramente...
REVIEW
Vitamin D, Obesity and Risk of Diabetes
Short running head: Vitamin D, obesity and diabetes
Giovanni De Pergola, Alida Ammirati, Domenico Caccavo,
Serena Bavaro, Barone Giuseppina
Ambulatorio di Nutrizione Clinica, U.O.C. di Oncologia Medica, Dipartimento
di Scienze Biomediche e Oncologia Umana (D.I.M.O.)
Università degli Studi di Bari ALDO MORO
Policlinico di Bari, Piazza Giulio Cesare, 70124 Bari
Address correspondence to:
Giovanni De Pergola
Via Putignani 236 - 70122 Bari Italy
Tel +39-080-5592909, Fax +39-080-5478831
e-mail: [email protected]
Abstract (English)
Vitamin D deficiency is newly recognized as a common condition of increasing
prevalence worldwide. Clinically, vitamin D has an established role in calcium and bone
metabolism, but lower vitamin levels are associated with obesity and an increased risk to
develop type 2 diabetes, cardiovascular diseases and cancer. The molecular mechanisms of
these associations are partially understood, but it is known that vitamin D stiumlates
lypolysis and inhibits adipogenesis in human adipocytes, and lower vitamin D may induce
body fat accumulation. Vitamin D receptors are expressed in both pancreatic β-cells and
skeletal muscle cells, and their activation results in increased insulin release and
responsiveness to insulin for glucose transport. Vitamin D is also newly recognized for
potent antiproliferative, prodifferentiative, and immunomodulatory effects in many tissues.
Vitamin D deficiency is frequently unrecognized clinically and, although laboratory
measurement is easy to perform and treatment of vitamin D deficiency is relatively well
tolerated and inexpensive, physicians are not sufficiently informed about effects of vitamin D
other than those on skeletal metabolism, and they rarely ask for plasma vitamin D
measurement. The purpose of this Review is to examine the association between vitamin D
deficiency, obesity and risk of type 2 diabetes.
Keywords: vitamin D, obesity, insulin, type 2 diabetes
Abstract (Italiano)
Il deficit di vitamina D è una condizione patologica in costante aumento nel mondo. E’
noto che la vitamin D ha un ruolo fondamentale sul metabolismo del calcio e dell’osso, ma
recentemente è stato dimostrato che il deficit di vitamina D è associato con la obesità ed un
maggiore rischio di sviluppare il diabete tipo 2, le malattie cardiovascolari ed il cancro. I
meccanismi molecolari di queste associazioni sono parzialmente conosciute, ma è noto che la
vitamina D favorisce la lipolisi e inibisce l’adipogenesi negli adipociti umani e che bassi
livelli di vitamina D possono favorire l’accumulo di grasso corporeo. Recettori per la
vitamina D sono espressi nelle cellule β-pancreatiche e nelle cellule del muscolo scheletrico e
la loro attivazione favorisce la secrezione d’insulina ed un aumento della responsività
all’insulina, per quanto concerne il trasporto del glucosio. Alla vitamin D viene anche
atttribuita una potente azione antiproliferativa, prodifferenziativa ed immunomodulatoria in
molti tessuti. Seppure sia frequente, il deficit di vitamin D non è comunemente riconosciuto
e, nonostante il dosaggio plasmatico sia facile da eseguire ed il trattamento con vitamina D
sia ben tollerato e poco costoso, i medici sono poco informati sugli effetti non scheletrici
della vitamina D, e raramente richiedono il dosaggio plasmatico della vitamina D. Lo scopo
di questa Review è quello di esaminare le attuali informazioni sulle associazioni tra deficit
della vitamina D, obesità e rischio di diabete tipo 2.
Introduction
Vitamin D deficiency (<75 nmol/l) is common in all age groups, with a dramatic increase
in prevalence (74%) and severity over the last decade (1,2). It has been estimated that 1
billion people worldwide are affected by various degrees of vitamin D deficiency (1), and the
National Health and Nutrition Examination Survey (NHANES) report has shown that the
prevalence of severe deficiency (<25 nmol/l) increased from 2 to 6% in the general USA
population and from 9 to 29% in non- Hispanic blacks (3).
Vitamin D is generated in the skin from the nonenzymatic conversion of provitamin D3
to previtamin D during exposure to sunlight emitting ultraviolet radiation in the narrow band
of 290 to 315 mm. Skin-derived synthesis of vitamin D is quite variable, depending on
pigmentation, latitude, season, clothing, age, exposure to sunlight, sunscreen use, local
weather conditions and dietary intake (1).
Dietary sources of vitamin D are limited, and some vitamin D comes from few food
sources (between 100 and 200 IU per day), since only certain kinds of fish contain sizable
amounts (Table 1).
Vitamin D is either stored in adipose tissue or converted in the liver by the enzyme 25-
hydroxylase to 25-hydroxyvitamin D3 (25[OH]D3 or 25(OH)D), that is a partially water-
soluble form, with a shorter half-life than vitamin D that circulates bound to vitamin D–
binding protein. Serum 25(OH)D level is the best indicator of overall vitamin D status
because this measurement reflects total vitamin D from dietary intake and sunlight exposure,
as well as the conversion of vitamin D from adipose stores in the liver (4). In healthy whites,
serum levels of 25(OH)D may vary according to environmental, hormonal, genetic, and
nutritional factors (1,4).
Several conditions cause very low serum levels of 25(OH)D (i.e., below 10 ng per
milliliter), including poor dietary intake of vitamin D coupled with negligible sun exposure,
malabsorption due to inflammatory bowel disease, gluten enteropathy, gastric surgery, biliary
disease, or intestinal overgrowth; use of antiseizure medications (e.g., phenobarbital or
phenytoin), and long-term use of glucocorticoids (1,4).
25-hydroxyvitamin D is converted to the active metabolite, 1,25-dihydroxyvitamin D
(1,25[OH]2D), or calcitriol, in the kidney, although other tissues have 1α-hydroxylase
enzymatic activity. Calcitriol circulates in lower concentrations than 25-hydroxyvitamin D,
but has much greater affinity for the vitamin D receptor and is biologically more potent.
The synthesis of calcitriol is enhanced by low levels of serum phosphate and by
parathyroid hormone (PTH), which rises in response to lower levels of serum calcium and
when levels of 25(OH)D fall below 30 ng per milliliter (1).
The well known role of vitamin D is in the calcium and bone metabolism, and most
observational and randomized, placebo-controlled trials concerning vitamin D have focused
on skeletal health outcomes and have linked low levels of 25(OH)D to fractures (1,5,6).
However, vitamin D is newly recognized for potent antiproliferative, prodifferentiative, and
immunomodulatory effects in many tissues (7), and a growing number of studies has reported
widespread vitamin D deficiency and insufficiency in apparently healthy populations, and in
patients with various pathologies (8).
Recently, attention has turned to nonskeletal effects of vitamin D insufficiency,
particularly in relation to obesity (1,2,4,9), diabetes mellitus (10,11), metabolic syndrome
(12,13), cardiovascular disease (14), cancer (15), and immune dysfunction (16).
Vitamin D and obesity
Central obesity is a major independent risk factor for type 2 diabetes (17). Interestingly,
obese patients have typically plasma levels in the range of 10 to 20 ng per milliliter (1,4), and
several studies in adults have demonstrated that serum 25(OH)D concentrations are inversely
correlated with various measures of obesity, including weight, BMI, and waist circumference
(1,2,4,18,19,20,21,22,23,24). The Framigham Heart Study has also showed that vitamin D
status is strongly associated with subcutaneous and, especially, visceral
adiposity (20). Cross-sectional studies in children indicated that plasma 25(OH)D
concentrations are inversely associated with body mass index (BMI; in kg/m2) (25–27) and
waist circumference (28,29). A study performed in healthy young women has also recently
shown that vitamin D insufficiency was associated with increased fat infiltration in muscle,
measured by CT scan (30). In line with all these studies, weight loss of 10%, obtained by a
20 weeks low-calorie diet, increased 25-OHD levels in obese women (31). Another study
confirmed that serum vitamin D levels were higher after weight loss induced by a 2-years
dietary intervention (32).
In a calcium-intervention trial in 69 pubertal children, a higher baseline vitamin D status
was significantly associated with less weight gain over 24 months in univariate analyses (33).
Another recent paper has shown that, after baseline adiposity and other potential confounders
were controlled for, vitamin D serostatus was inversely associated with the development of
adiposity in a study performed in 479 schoolchildren aged 5–12 years (34). The Women’s
Health Initiative, which is a large trial that assigned women to receive either 1000 mg Ca
plus 400 IU vitamin D/d or a placebo reported that women who received the regimen of
calcium and vitamin D had a small significant lower gain in BMI and waist circumference
over 7 y of follow-up (35); in that study, it was impossible to separate the effects of calcium
and vitamin D.
Why obese individuals are more likely to have low serum 25(OH)D concentrations? First,
since 25(OH)D has a high lipid-solubility, it may well be that this vitamin is under
sequestration when adipose tissue is in excess, resulting in reduced 25(OH)D bioavailability
(9). An alternate explanation is that obese individuals have less exposure to ultraviolet light
because of lower levels of outdoor physical activity, which would result in lower serum
25(OH)D concentrations. It is to note that lower vitamin D may induce body fat
accumulation since vitamin D stimulates lypolysis (36,37) and inhibits adipogenesis (38,39)
in human adipocytes, through its role in regulating intracellular calcium concentrations. In
particular, in vitro studies have also shown that vitamin D can inhibit the expression of a key
adipogenesis regulator, peroxisome proliferator-activated receptor-gamma (38,39).
In contrast with previous studies, a trial of overweight adults showed that
supplementation with either 20,000 or 40,000 IU cholecalciferol/wk and 500 mg Ca/d did not
lead to significantly greater weight loss than the calcium-only control group (40); however,
none of the groups experienced significant weight changes over the 1-y study period.
Evidence of beneficial effect of vitamin D supplementation on weight reduction is lacking
also in other studies (41). It is possible that vitamin D may limit weight gain but does not
affect long-term weight loss in individuals who are already overweight. Moreover, a
prospective study performed in older subjects showed that the association between measures
of body adiposity and change in 25-(OH)D completely disappeared after adjustment for
leptin and diminished after adjustment for IL-6 (42). The authors suggested that obesity-
related vitamin D deficiency may be mediated by leptin and, to a lesser extent, by IL-6, and
that it is possible that leptin and IL-6 secreted by adipose tissue have inhibitory effects on 25-
(OH)D synthesis via their receptors. Alternatively, since leptin and IL-6 are associated with
insulin resistance, it may well be that hyperinsulinemia may downregulate liver 25-
hydroxylase, resulting in decreased formation of 25-(OH)D.
Actually, only randomized trials or longitudinal studies that were adjusted for baseline
adiposity could help to explain causation, but there is limited and inconsistent evidence of the
association between vitamin D and adiposity from prospective studies.
Vitamin D and risk of type 2 diabetes
25(OH)D has been shown to correlate inversely with fasting serum glucose in nondiabetic
postmenopausal women (21). The National Health and Nutrition Examination Survey 2001–
2006 showed that low serum vitamin D levels elevate the risk for early-stage diabetes
(prediabetes), adjusting for age, sex and BMI (43). Similar finding have been shown by a
recent study performed in a nationally representative sample of U.S. adults, who were free of
clinical cardiovascular diseases and diabetes, showing that lower serum 25(OH)D levels are
associated with prediabetes, after adjusting for potential confounders, including age, sex,
race/ethnicity, smoking, alcohol intake, BMI, physical activity, hypertension, systolic blood
pressure, serum total cholesterol, serum C-reactive protein levels, and estimated glomerular
filtration rate (44). Some evidence suggests that 25(OH)D insufficiency may be involved in
the development of diabetes (10,11). Hypovitaminosis D is associated with increased
diabetes prevalence and insulin resistance assessed by fasting glucose and insulin levels in
non-Hispanic whites and Mexican Americans (45). A significant inverse association was
observed between serum 25(OH)D concentration and type 2 diabetes incidence in a 17-year
observational Finish study (44). Baseline 25(OH)D was inversely associated with 10-year
risk of hyperglycemia (fasting glucose and 2 h post-OGTT) and insulin resistance (fasting
insulin and homeostasis model assessment of insulin resistance (HOMA-IR) ) in a
prospective population-based study of 524 middle-aged nondiabetic men and women (47).
Over a 7-y average follow-up of the Framingham Offspring Study, subjects in the highest
tertile of the predicted 25(OH)D score at baseline had a 40% lower incidence of type 2
diabetes in comparison with individuals in the lowest tertile, after adjustment for age, sex,
waist circumference, parental history of type 2 diabetes, hypertension, low HDL cholesterol,
elevated triglycerides, impaired fasting glucose, and Dietary Guidelines for Americans
Adherence Index score (48). Although these and some other epidemiologic studies (49) have
reported an association between low serum 25(OH)D levels (below 30 ng/ml) and diabetes,
others did not find an independent association after multivariable adjustment for confounding
variables (50,51), or in subgroup analyses in women (52).
A recent meta-analysis suggested that there is insufficient evidence to conclude that an
inverse association exists between 25(OH)D levels and diabetes (53). Since reduced kidney
function is responsible for lower renal 1-a hydroxylase activity, a deficit in kidney function
in diabetes may be a potential confounder in the association between 25(OH)D levels and
this metabolic disease (54,55). Markers of inflammation have been shown to be associated
with both diabetes (56) and low 25(OH)D levels (57), thus resulting as further possible
confounding variables in the relationship between vitamin D and diabetes
Pharmacologic doses of 1,25-dihydroxyvitamin D3 have been shown to delay the onset of
diabetes in animal models of diabetes (58). Unfortunately, only few intervention studies
evaluated the effects of vitamin D supplementation on glucose metabolism. High-dose
calcitriol (1.5mg daily for 7 days) did not increase insulin sensitivity measured by
euglycemic clamp compared with placebo in healthy volunteers who were not vitamin D
deficient at baseline (59). However, 1-month treatment with cholecalciferol (1332 IU daily)
improved insulin sensitivity and first-phase insulin secretion in 10 women with T2DM (of
whom seven were vitamin D deficient at baseline), albeit with no effect on second-phase
insulin secretion (60). Interestingly, daily intake of a vitamin D–fortified yogurt drink, either
with or without added calcium, improved glycemic status in patients affected by type 2
diabetes (T2D) (61). Actually, clinical studies designed specifically to assess the effect of
vitamin D supplementation on glucose metabolism are currently underway at N.I.H.
(National Institute of Health). These studies are evaluating the effect of vitamin D
supplementation in high-risk populations with both vitamin D deficiency and impaired
glucose metabolism. Larger doses of vitamin D (2000–7000 IU daily) are currently used, and
the results of these studies will be informative.
Cohort studies have documented a reduced risk of diabetes when higher dietary calcium
and vitamin D intake are associated (52,62). Calcium may have a confounding effect on the
influence of vitamin D on risk to develop diabetes in these studies, and it is to note that
calcium intake could indirectly lead to an improvement in vitamin D status because
there would be less need for conversion of 25(OH)D to 1,25-dihydroxyvitamin D (63).
It is noteworthy that the Australian Diabetes, Obesity and Lifestyle (AusDiab) study, a
large population-based prospective study, showed that higher serum 25OHD levels, but not
higher dietary calcium, were associated with a significantly reduced risk of diabetes in
Australian adult men and women, after adjusting for traditional risk factors (64). The use of
OGTT to diagnose diabetes ensured that all incident cases were included in this study (64).
In contrast with the previous findings, other studies do not support a positive effect of
vitamin D on glucose tolerance. For example, a 1-year study performed in a total of 330
overweight or obese subjects (21-70 years old) showed that subjects randomized to
cholecalciferol (20.000 or 40.000 IU per week) and calcium (500 mg daily) did not obtain an
improvement of glucose tolerance (65). Moreover, the Women’s Health Initiative trial,
involving postmenopausal women, showed that treatment with calcium and 25(OH)D3 (at
lower doses than in other studies) did not reduce the risk of developing diabetes, defined by
self-report (66).
Vitamin D, insulin secretion and insulin effect
Which are the mechanisms linking vitamin D to glucose metabolism, insulin and risk of
diabetes? An inverse associations between vitamin D and fasting insulin concentrations or
HOMA-IR index have been reported in most of the studies performed in adults
(45,48,67,68,69,70), even independently of BMI or obesity (70). Only one epidemiological
study could not find this relationship (71). Concerning adolescent subjects, the National
Health and Nutrition Examination Survey, performed between 2001 and 2006, confirmed an
inverse association between vitamin D and insulin serum levels in adolescent male subjects
(72). As far as insulin secretion is concerned, it is now accepted that vitamin D increases
insulin secretion either in animal models (58,73,74,75) or in humans (60,76,77). Concerning
insulin effect, two randomized controlled trials of high-dose vitamin D supplementation
showed a significant increase in insulin sensitivity in insulin-resistant Indian men or South-
Asian women, either after 6 weeks or 6 months of treatment, respectively (78,79). Most of
studies have confirmed that vitamin D increases insulin sensitivity, independently of other
mechanisms influencing insulin effect (BMI, body fat distribution, etc) (77,80,81).
Moreover, treatment with 25(OH)D3 and calcium attenuated a rise in fasting glucose and
progression of insulin resistance in a placebo controlled trial of nondiabetic subjects with
impaired fasting glucose (82). Interestingly, the Australian Diabetes Obesity and Lifestyle
(AusDiab) study showed that serum 25OHD was positively and independently associated
with HOMA-S, a marker of insulin sensitivity, whereas dietary calcium intake was not
associated with either HOMA-S or type 2 diabetes risk (66). The conclusions of these studies
are reinforced by the finding that weight loss of 10%, obtained after 20 weeks of low-calorie
diet, increased 25-OHD levels in obese women, and this increase was mainly associated with
improvement of insulin resistance (30).
The expression of vitamin D receptors in both pancreatic β-cells and skeletal muscle
cells, which, upon activation by vitamin D supplementation, result in increased insulin
release and responsiveness to insulin for glucose transport (60), may serve as an underlying
mechanism to explain correlation between vitamin D and risk of diabetes. Interestingly,
evidence from in vitro studies suggests that vitamin D may alter insulin sensitivity via a
direct stimulatory effect on insulin receptor expression (83), modulation of inflammation
(84), and adiponectin levels (85).
Only some studies do not confirm the protective effect of vitamin D on the risk of
diabetes. For example, a recent study performed in middle-aged Italian men and women
reported that 25(OH)D concentrations were associated with euglycemic clamp-derived
insulin sensitivity, but not after adjustment for BMI (86). Seemingly, the association of
25(OH)D with the measures of insulin resistance were not significant after
adjustment for VAT in the Framingham Heart Study (20). Alvarez et al have
suggested that 25(OH)D may be more clinically relevant to insulin sensitivity in vitamin D–
insufficient subjects (80).
PTH, vitamin D and risk of diabetes
Even though PTH is positively associated with insulin sensitivity (87), and PTH levels
are often elevated in vitamin D-deficient states (1), 25(OH)D and PTH concentrations have
been shown to be independently associated with whole-body insulin sensitivity in a cohort of
healthy women (80). These results suggest that 25(OH)D and PTH may influence insulin
sensitivity through independent mechanisms (80).
Vitamin D in patients with type 2 diabetes
Concerning patients affected by type 2 diabetes, serum 25(OH)D have been shown to be
inversely associated with hemoglobin A1c (HbA1C), especially in participants with higher
BMI, and at concentrations less than 65 nmol/l (88). Hypovitaminosis D is more prevalent in
patients with type 2 diabetes than in those without diabetes (89). Lastly, 1-month treatment
with daily cholecalciferol improved insulin sensitivity and first-phase insulin secretion in
women affected by type 2 diabetes (60).
Bibliografia
1) Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-81.
2) Hypponen E, Power C. Hypovitaminosis D in British adults at age 45 y: nationwide cohort
study of dietary and lifestyle predictors. Am J Clin Nutr 2007; 85: 860-8
3) Ginde AA, Liu MC, Camargo CA Jr. Demographic differences and trends of vitamin D
insufficiency in the US population, 1988–2004. Arch Intern Med 2009; 169: 626-32
4) IOM report on calcium and vitamin D. Washington, DC: Institute of Medicine, 2010.
(http://www.iom.edu/vitaminD.)
5) Dawson-Hughes B. Serum 25-hydroxyvitamin D and functional outcomes in the elderly.
Am J Clin Nutr 2008; 88: 537S-540S.
6) van Schoor NM, Visser M, Pluijm SM, Kuchuk N, Smit JH, Lips P. Vitamin D deficiency
as a risk factor for osteoporotic fractures. Bone 2008; 42: 260-6.
7) Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands.
Endocr Rev 2005; 26: 662-87
8) Vieth R, Cole DE, Hawker GA, Trang HM, Rubin LA. Wintertime vitamin D
insufficiency is common in young Canadian women, and their vitamin D intake does not prevent
it. Eur J Clin Nutr 2001; 55: 1091-7
9) Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of
vitamin D in obesity. Am J Clin Nutr 2000; 72: 690-3
10) Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type
2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 2007; 92: 2017-29
11) Mathieu C, Gysemans C, Giulietti A, Bouillon R. Vitamin D and diabetes. Diabetologia
2005; 48: 1247-1257
12) Florentin M, Elisaf MS, Mikhailidis DP, Liberopoulos EN. Vitamin D and metabolic
syndrome: is there a link? Curr Pharm Des 2010; 16: 3417-34
13) Chacko SA, Song Y, Manson JE, et al Serum 25-hydroxyvitamin D concentrations in
relation to cardiometabolic risk factors and metabolic syndrome in postmenopausal women. Am
J Clin Nutr 2011; 94: 209-17
14) Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25-
hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular
mortality. Arch Intern Med 2008; 168: 1340-9
15) Giovannucci E, Liu Y, Rimm EB, et al. Prospective study of predictors of vitamin D
status and cancer incidence and mortality in men. J Natl Cancer Inst 2006; 98: 451-9.
16) Hewison M. Vitamin D and innate immunity. Curr Opin Investig Drugs 2008; 9: 485-90
17) Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes
epidemic. Nature 2001; 414: 782-7
18) Parikh SJ, Edelman M, Uwaifo GI, et al. The relationship between obesity and serum
1,25-dihydroxy vitamin D concentrations in healthy adults. J Clin Endocrinol Metab 2004; 89:
1196-9
19) Nesby-O’Dell S, Scanlon KS, Cogswell ME, et al. Hypovitaminosis D prevalence and
determinants among African American and white women of reproductive age: third National
Health and Nutrition Examination Survey, 1988-1994. Am J Clin Nutr 2002; 76: 187-92
20) Cheng S, Massaro JM, Fox CS, et al. Adiposity, cardiometabolic risk, and vitamin D
status: the Framingham Heart Study. Diabetes 2010; 59: 242-8
21) Need AG, O’Loughlin PD, Horowitz M, Nordin BE. Relationship between fasting serum
glucose, age, body mass index and serum 25 hydroxyvitamin D in postmenopausal women. Clin
Endocrinol (Oxf) 2005; 62: 738-41
22) Macdonald HM, Mavroeidi A, Barr RJ, et al. Vitamin D status in postmenopausal
women living at higher latitudes in the UK in relation to bone health, overweight, sunlight
exposure and dietary vitamin D. Bone 2008; 42: 996-1003
23) Konradsen S, Ag H, Lindberg F, et al. Serum 1,25-dihydroxy vitamin D is inversely
associated with body mass index. Eur J Nutr 2008; 47: 87-91
24) Ford ES, Ajani UA, McGuire LC, Liu S. Concentrations of serum vitamin D and the
metabolic syndrome among U.S. adults. Diabetes Care 2005; 28: 1228-30
25) Alemzadeh R, Kichler J, Babar G, Calhoun M. Hypovitaminosis D in obese children and
adolescents: relationship with adiposity, insulin sensitivity, ethnicity, and season. Metabolism
2008; 57: 183-91
26) Smotkin-Tangorra M, Purushothaman R, Gupta A, Nejati G, Anhalt H, Ten S.
Prevalence of vitamin D insufficiency in obese children and adolescents. J Pediatr Endocrinol
Metab 2007; 20: 817-23
27) Kumar J, Muntner P, Kaskel FJ, Hailpern SM, Melamed ML. Prevalence and
associations of 25-hydroxyvitamin D deficiency in US children: NHANES 2001-2004. Pediatrics
2009; 124: E362-70
28) Rodrıguez-Rodrıguez E, Navia-Lomban B, Lopez-Sobaler AM, Ortega RM. Associations
between abdominal fat and body mass index on vitamin D status in a group of Spanish
schoolchildren. Eur J Clin Nutr 2010; 64: 461-7
29) Elizondo-Montemayor L, Ugalde-Casas PA, Serrano-Gonzalez M, Cuello-Garcia CA,
Borbolla-Escoboza JR. Serum 25-hydroxyvitamin d concentration, life factors and obesity in
mexican children. Obesity 2010; 18: 1805-11
30) Gilsanz V, Kremer A, Mo AO, Wren TAL, Kremer R Vitamin D status and its relation to
muscle mass and muscle fat in young women. J Clin Endocrinol Metab 2010; 95: 1595-601
31) Tzotzas T, Papadopoulou FG, Tziomalos K, et al Rising serum 25-hydroxy-vitamin D
levels after weight loss in obese women correlate with improvement in insulin resistance. J Cli
Endocrinol Metab 2010; 95: 4251-7
32) Shahar DR, Schwarzfuchs D, Fraser D, and the DIRECT Group. Dairy calcium intake,
serum vitamin D, and successful weight loss. Am J Clin Nutr 2010; 92: 1017-22
33) Tylavsky FA, Cheng SL, Lyytikainen A, Viljakainen H, Lamberg-Allardt C. Strategies to
improve vitamin D status in northern European children: Exploring the merits of vitamin D
fortification and supplementation. J Nutr 2006; 136: 1130-4
34) Gilbert-Diamond, Baylin A, Mora-Plazas M, et al Vitamin D deficiency and
anthropometric indicators of adiposity in school-age children: a prospective study. Am J Clin
Nutr 2010; 92:1446–51
35) Hsia J, Heiss G, Ren H, et al. Calcium/vitamin D supplementation and cardiovascular
events. Circulation 2007; 115: 846-54
36) Zemel MB, Shi H, Greer B, Dirienzo D, Zemel PC. Regulation of adiposity by dietary
calcium. FASEB J 2000; 14: 1132-8
37) Xue B, Greenberg AG, Kraemer FB, Zemel MB. Mechanism of intracellular calcium
([Ca2+]i) inhibition of lipolysis in human adipocytes. FASEB J 2001; 15: 2527-9
38) Wood RJ. Vitamin D and adipogenesis: new molecular insights. Nutr Rev 2008; 66: 40-6
39) Kong J, Li YC. Molecular mechanism of 1,25-dihydroxyvitamin D-3 inhibition of
adipogenesis in 3T3-L1 cells. Am J Physiol Endocrinol Metab 2006; 290: E916-24
40) Sneve M, Figenschau Y, Jorde R. Supplementation with cholecalciferol does not
result in weight reduction in overweight and obese subjects. Eur J Endocrinol 2008; 159:
675-84
41) Major GC, Alarie FP, Dore J, Tremblay A. Calcium plus vitamin D supplementation and
fat mass loss in female very low-calcium consumers: potential link with a calcium-specific
appetite control. Br J Nutr 2009; 101: 659-63
42) Ding C, Parameswaran V, Blizzard L, Burgess J, Jones G Not a simple fat-soluble
vitamin: changes in serum25-(OH)D levels are predicted by adiposity and adipocytokines in
older adults. J Intern Med 2010; 268: 501-10
43) Gupta AK, Brashear MM, Johnson WD Prediabetes and prehypertension in healthy
adults are associated with low vitamin D levels. Diabetes Care 2011; 34. 658-60
44) Shankar A, Sabanayagam C, Kalidinidi S Serum 25-Hydroxyvitamin D levels and
prediabetes among subjects free of diabetes. Diabetes Care 2011; DOI: 10.2337/dc10-1203
45) Scragg R, Sowers M, Bell C; Third National Health and Nutrition Examination Survey.
Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition
Examination Survey. Diabetes Care 2004; 27: 2813-8
46) Mattila C, Knekt P, Männistö S, et al. Serum 25-hydroxyvitamin D concentration and
subsequent risk of type 2 diabetes. Diabetes Care 2007; 30: 2569-70
47) Forouhi NG, Luan J, Cooper A, Boucher BJ, Wareham NJ. Baseline serum 25-hydroxy
vitamin D is predictive of future glycemic status and insulin resistance the Medical Research
Council Ely Prospective Study 1990-2000. Diabetes 2008; 57: 2619-25
48) Liu E, Meigs JB, Pittas AG, et al. Predicted 25-hydroxyvitamin D score and incident type
2 diabetes in the Framingham Offspring Study. Am J Clin Nutr 2010; 91: 1627-33
49) Pittas AG, Dawson-Hughes B, Li T, et al. Vitamin D and calcium intake in relation to
type 2 diabetes in women. Diabetes Care 2006; 29: 650-6
50) Pittas AG, Sun Q, Manson JE, Dawson-Hughes B, Hu FB. Plasma 25-Hydroxyvitamin D
concentration and risk of incident type 2 diabetes in women. Diabetes Care 2010; 33: 2021-3.
51) Liu S, Song Y, Ford ES,Manson JE, Buring JE, Ridker PM. Dietary calcium, vitamin D,
and the prevalence of metabolic syndrome in middle-aged and older U.S. women. Diabetes Care
2005; 28: 2926-32
52) Knekt P, Laaksonen M, Mattila C, et al. Serum vitamin D and subsequent occurrence of
type 2 diabetes. Epidemiology 2008; 19: 666-71
53) Pittas AG, Chung M, Trikalinos T, et al. Systematic review: vitamin D and
cardiometabolic outcomes. Ann Intern Med 2010; 152: 307-14
54) Pitts TO, Piraino BH, Mitro R, et al. Hyperparathyroidism and 1,25-dihydroxyvitamin D
deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab 1988; 67: 876-81
55) Donahue RP, Stranges S, Rejman K, Rafalson LB, Dmochowski J, Trevisan M. Elevated
cystatin C concentration and progression to pre-diabetes: the Western New York study. Diabetes
Care 2007; 30: 1724-9
56) Shankar A, Li J. Positive association between high-sensitivity C-reactive protein level
and diabetes mellitus among US non-Hispanic black adults. Exp Clin Endocrinol Diabetes 2008;
116: 455-60
57) Manolagas SC, Provvedini DM, Tsoukas CD. Interactions of 1,25-dihydroxyvitamin D3
and the immune system. Mol Cell Endocrinol 1985; 43: 113-22
58) Mathieu C, Waer M, Laureys J, Rutgeerts O, Bouillon R. Prevention of autoimmune
diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia 1994; 37: 552-8
59) Fliser D, Stefanski A, Franek E, et al. No effect of calcitriol on insulin-mediated glucose
uptake in healthy subjects. Eur J Clin Invest 1997; 27: 629-33
60) Borissova AM, Tankova T, Kirilov G, Dakovska L, Kovacheva R. The effect of vitamin
D3 on insulin secretion and peripheral insulin sensitivity in type 2 diabetic patients. Int J Clin
Pract 2003; 57: 258-61
61) Bahareh N, Tirang RN, Maryamosadat F, et al. Daily consumption of vitamin D– or
vitamin D + calcium–fortified yogurt drink improved glycemic control in patients with type 2
diabetes: a randomized clinical trial. Am J Clin Nutr 2011; 93: 764-71
62) Reddy Vanga S, Good M, Howard PA, Vacek JL. Role of vitamin D in cardiovascular
health. Am J Cardiol 2010; 106: 798-805
63) Jacqmain M, Doucet E, Despres JP, Bouchard C, Tremblay A. Calcium intake, body
composition, and lipoprotein-lipid concentrations in adults. Am J Clin Nutr 2003; 77: 1448-
52
64) Gagnon C, Lu ZX, Magliano DJ, et al. Serum 25-Hydroxyvitamin D, calcium intake, and
risk of type 2 diabetes after 5 years. Diabetes Care 2011; 34: 1133-8
65) Jorde R, Sneve M, Torjesen P, Figenschau Y No improvement in cardiovascular risk
factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year. J
Intern Med 2010; 267: 462-72
66) de Boer IH, Tinker LF, Connelly S, et al. Women’s Health Initiative Investigators.
Calcium plus vitamin D supplementation and the risk of incident diabetes in the Women’s Health
Initiative. Diabetes Care 2008; 31: 701-7
67) Chiu KC, Chu A, Go VLW, Saad MF. Hypovitaminosis D is associated with insulin
resistance and beta cell dysfunction. Am J Clin Nutr 2004; 79:820-5
68) Liu E, Meigs JB, Pittas AG, et al. Plasma 25-hydroxyvitamin D is associated with
markers of the insulin resistant phenotype in nondiabetic adults. J Nutr 2009; 139: 329-34
69) Lu L, Yu Z, Pan A, et al Plasma 25-hydroxyvitamin D concentration and metabolic
syndrome among middle-aged and elderly Chinese individuals. Diabetes Care 2009; 32: 1278-83
70) Zhao G, Ford ES, Li C. Associations of serum concentrations of 25-hydroxyvitamin D
and parathyroid hormone with surrogate markers of insulin resistance among U.S. adults without
physician-diagnosed diabetes: NHANES, 2003–2006. Diabetes Care 2010; 33: 344-7
71) Gannage´-Yared MH, Chedid R, Khalife S, Azzi E, Zoghbi F, Halaby G. Vitamin D in
relation to metabolic risk factors, insulin sensitivity and adiponectin in a young middle-Eastern
population. Eur J Endocrinol 2009; 160: 965-71
72) Ford ES, Zhao G, Tsai J, Li C. Associations between concentrations of vitamin D and
concentrations of insulin, glucose, and HbA1c among adolescents in the United States. Diabetes
Care 2011; 34: 646-8
73) Norman AW, Frankel JB, Heldt AM, Grodsky GM. Vitamin D deficiency inhibits
pancreatic secretion of insulin. Science 1980; 209: 823-5
74) Chertow BS, Sivitz WI, Baranetsky NG, Clark SA, Waite A, Deluca HF. Cellular
mechanisms of insulin release: the effects of vitamin D deficiency and repletion on rat insulin
secretion. Endocrinology 1983; 113: 1511–8
75) Cade C, Norman AW. Vitamin D3 improves impaired glucose tolerance and insulin
secretion in the vitamin D-deficient rat in vivo. Endocrinology 1986; 119: 84-90
76) Boucher BJ, Mannan N, Noonan K, Hales CN, Evans SJW. Glucose intolerance and
impairment of insulin secretion in relation to vitamin D deficiency in East London Asians.
Diabetologia 1995; 38:1239-45
77) Kayaniyil S, Vieth R, Retnakaran R, et al. Association of vitamin D with insulin
resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes. Diabetes Care 2010;
33: 1379-81
78) Nagpal J, Pande JN, Bhartia A. A double blind, randomized, placebo-controlled trial of
the short-term effect of vitamin D3 supplementation on insulin sensitivity in apparently healthy,
middle-aged, centrally obese men. Diabet Med 2009; 26: 19-27
79) von Hurst PR, Stonehouse W, Coad J. Vitamin D supplementation reduces insulin
resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D
deficient-a randomised, placebo-controlled trial. Br J Nutr 2010; 103: 549-55
80) Alvarez JA, Ashraf AP, Hunter GR, Gower BA Serum 25-hydroxyvitamin D and
parathyroid hormone are independent determinants of whole-body insulin sensitivity in women
and may contribute to lower insulin sensitivity in African Americans. Am J Clin Nutr 2010; 92:
1344-9
81) Kamycheva E, Jorde R, Figenschau Y, Haug E. Insulin sensitivity in subjects with
secondary hyperparathyroidism and the effect of a low serum 25-hydroxyvitamin D level on
insulin sensitivity. J Endocrinol Invest 2007; 30: 126-32
82) Pittas AG, Harris SS, Stark PC, Dawson-Hughes B. The effects of calcium and vitamin D
supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes
Care 2007; 30: 980-6
83) Maestro B, Campión J, Dávila N, Calle C. Stimulation by 1,25-dihydroxyvitamin D3 of
insulin receptor expression and insulin responsiveness for glucose transport in U-937 human
promonocytic cells. Endocr J 2000; 47: 383-91
84) Giulietti A, van Etten E, Overbergh L, Stoffels K, Bouillon R, Mathieu C. Monocytes
from type 2 diabetic patients have a pro-inflammatory profile. 1,25-Dihydroxyvitamin D(3)
works as anti-inflammatory. Diabetes Res Clin Pract 2007; 77: 47-57
85) Nimitphong H, Chanprasertyothin S, Jongjaroenprasert W, Ongphiphadhanakul B. The
association between vitamin D status and circulating adiponectin independent of adiposity in
subjects with abnormal glucose tolerance. Endocrine 2009; 36: 205-10
86) Muscogiuri G, Sorice GP, Prioletta A, et al. 25-Hydroxyvitamin D concentration
correlates with insulin-sensitivity and BMI in obesity. Obesity 2010; 18: 1906-10
87) Chiu KC, Chuang LM, Lee NP, et al. Insulin sensitivity is inversely correlated with
plasma intact parathyroid hormone level. Metabolism 2000; 49: 1501-5
88) Hypponen E, Power C. Vitamin D status and glucose homeostasis in the 1958 British
birth cohort: the role of obesity. Diabetes Care 2006; 29: 2244-6
89) Targher G, Bertolini L, Padovani R, et al. Serum 25-hydroxyvitamin D3 concentrations
and carotid artery intima-media thickness among type 2 diabetic patients. Clin Endocrinol (Oxf)
2006; 65: 593-7